![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Grants SGX Orphan-Drug Designation for Troxatyl
FDA Grants SGX Orphan-Drug Designation for Troxatyl
May 23, 2005
Structural GenomiX's lead product candidate, Troxatyl, has received orphan-drug status from the FDA.
Troxatyl (troxacitabine) is a novel nucleoside analog being evaluated by the company in a Phase I/II trial for the treatment of relapsed acute myelogenous leukemia (AML) and in a Phase I/II trial for the treatment of various solid tumors. Structural GenomiX plans to complete the Phase I/II AML trial and progress Troxatyl into a Phase II trial in relapsed and/or refractory adult AML patients in mid-2005.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct